

2017 HCPCS Deleted Codes

Code	Short Description	Long Description	Date
A4466	Elastic garment/covering	Garment, belt, sleeve or other covering, elastic or similar stretchable material, any type, each	20161231
A9544	I131 tositumomab, dx	Iodine i-131 tositumomab, diagnostic, per study dose	20161231
A9545	I131 tositumomab, rx	Iodine i-131 tositumomab, therapeutic, per treatment dose	20161231
B9000	Enter infusion pump w/o alrm	Enteral nutrition infusion pump - without alarm	20161231
C9121	Injection, argatroban	Injection, argatroban, per 5 mg	20161231
C9137	Adynovate factor viii recom	Injection, factor viii (antihemophilic factor, recombinant) pegylated, 1 i.u.	20161231
C9138	Nuwiq factor viii recomb	Injection, factor viii (antihemophilic factor, recombinant) (nuwiq), 1 i.u.	20161231
C9139	Idelvion, 1 i.u.	Injection, factor ix, albumin fusion protein (recombinant), idelvion, 1 i.u.	20161231
C9349	Puraply, puraply antimic	Puraply, and puraply antimicrobial, any type, per square centimeter	20161231
C9458	Florbetaben f18	Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries	20160630
C9459	Flutemetamol f18	Flutemetamol f18, diagnostic, per study dose, up to 5 millicuries	20160630
C9461	Choline c 11, diagnostic	Choline c 11, diagnostic, per study dose	20161231
C9470	Aripiprazole lauroxil im	Injection, aripiprazole lauroxil, 1 mg	20161231
C9471	Hymovis, 1 mg	Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg	20161231
C9472	Inj talimogene laherparepvec	Injection, talimogene laherparepvec, 1 million plaque forming units (pfu)	20161231
C9473	Injection, mepolizumab	Injection, mepolizumab, 1 mg	20161231
C9474	Inj, irinotecan liposome	Injection, irinotecan liposome, 1 mg	20161231
C9475	Injection, necitumumab	Injection, necitumumab, 1 mg	20161231
C9476	Injection, daratumumab	Injection, daratumumab, 10 mg	20161231
C9477	Injection, elotuzumab	Injection, elotuzumab, 1 mg	20161231
C9478	Injection, sebelipase alfa	Injection, sebelipase alfa, 1 mg	20161231
C9479	Instill, ciprofloxacin otic	Instillation, ciprofloxacin otic suspension, 6 mg	20161231
C9480	Injection, trabectedin	Injection, trabectedin, 0.1 mg	20161231
C9481	Injection, reslizumab	Injection, reslizumab, 1 mg	20161231
C9742	Laryngoscopy with injection	Laryngoscopy, flexible fiberoptic, with injection into vocal cord(s), therapeutic, including diagnostic laryngoscopy, if performed	20161231
C9743	Bulking/spacer material impl	Injection/implantation of bulking or spacer material (any type) with or without image guidance (not to be used if a more specific code applies)	20160630
C9800	Dermal filler inj px/suppl	Dermal injection procedure(s) for facial lipodystrophy syndrome (lds) and provision of radiesse or sculptra dermal filler, including all items and supplies	20161231
E0628	Seat lift for pt furn-electr	Separate seat lift mechanism for use with patient owned furniture-electric	20161231
G0154	Hhcop-svs of rn,ea 15 min	Direct skilled nursing services of a licensed nurse (lpn or rn) in the home health or hospice setting, each 15 minutes	20160229

G0163	Hhc lpn/rn obs/asses ea 15	Skilled services of a licensed nurse (lpn or rn) for the observation and assessment of the patient's condition, each 15 minutes (the change in the patient's condition requires skilled nursing personnel to identify and evaluate the patient's need for possible modification of treatment in the home health or hospice setting)	20161231
G0164	Hhc lis nurse train ea 15	Skilled services of a licensed nurse (lpn or rn), in the training and/or education of a patient or family member, in the home health or hospice setting, each 15 minutes	20161231
G0389	Ultrasound exam aaa screen	Ultrasound b-scan and/or real time with image documentation; for abdominal aortic aneurysm (aaa) screening	20161231
G0436	Tobacco-use counsel 3-10 min	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	20160930
G0437	Tobacco-use counsel>10min	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	20160930
G3001	Admin + supply, tositumomab	Administration and supply of tositumomab, 450 mg	20161231
G8401	Pt inelig osteo screen measu	Clinician documented that patient was not an eligible candidate for screening	20161231
G8458	Pt inelig geno no antivir tx	Clinician documented that patient is not an eligible candidate for genotype testing; patient not receiving antiviral treatment for hepatitis c during the measurement period (e.g. genotype test done prior to the reporting period, patient declines, patient not a candidate for antiviral treatment)	20161231
G8460	Pt inelig rna no antivir tx	Clinician documented that patient is not an eligible candidate for quantitative rna testing at week 12; patient not receiving antiviral treatment for hepatitis c	20161231
G8461	Pt rec antivir treat hep c	Patient receiving antiviral treatment for hepatitis c during the measurement period	20161231
G8485	Report, diabetes measures	I intend to report the diabetes mellitus (dm) measures group	20161231
G8486	Report, prev care measures	I intend to report the preventive care measures group	20161231
G8487	Report ckd measures	I intend to report the chronic kidney disease (ckd) measures group	20161231
G8489	Cad measures grp	I intend to report the coronary artery disease (cad) measures group	20161231
G8490	Ra measures grp	I intend to report the rheumatoid arthritis (ra) measures group	20161231
G8491	Hiv/aids measures grp	I intend to report the hiv/aids measures group	20161231
G8494	Dm meas qual act perform	All quality actions for the applicable measures in the diabetes mellitus (dm) measures group have been performed for this patient	20161231
G8495	Ckd meas qual act perform	All quality actions for the applicable measures in the chronic kidney disease (ckd) measures group have been performed for this patient	20161231
G8496	Prev care mg qual act perfrm	All quality actions for the applicable measures in the preventive care measures group have been performed for this patient	20161231

G8497	Cabg meas qual act perform	All quality actions for the applicable measures in the coronary artery bypass graft (cabg) measures group have been performed for this patient	20161231
G8498	Cad meas qual act perform	All quality actions for the applicable measures in the coronary artery disease (cad) measures group have been performed for this patient	20161231
G8499	Ra meas qual act perform	All quality actions for the applicable measures in the rheumatoid arthritis (ra) measures group have been performed for this patient	20161231
G8500	Hiv meas qual act perform	All quality actions for the applicable measures in the hiv/aids measures group have been performed for this patient	20161231
G8544	Cabg measures grp	I intend to report the coronary artery bypass graft (cabg) measures group	20161231
G8545	Hepc measures grp	I intend to report the hepatitis c measures group	20161231
G8548	Hf measures grp	I intend to report the heart failure (hf) measures group	20161231
G8549	Hepc mg qual act perform	All quality actions for the applicable measures in the hepatitis c measures group have been performed for this patient	20161231
G8551	Hf mg qual act perform	All quality actions for the applicable measures in the heart failure (hf) measures group have been performed for this patient	20161231
G8634	Pt no elg phar ther osteo	Clinician documented patient not an eligible candidate to receive pharmacologic therapy for osteoporosis	20161231
G8645	Asthma measures grp	I intend to report the asthma measures group	20161231
G8646	Asthma mg qual act perform	All quality actions for the applicable measures in the asthma measures group have been performed for this patient	20161231
G8725	Lipid profile perf doc	Fasting lipid profile performed (triglycerides, ldl-c, hdl-c and total cholesterol)	20161231
G8726	Doc reas no lipid profile	Clinician has documented reason for not performing fasting lipid profile (e.g., patient declined, other patient reasons)	20161231
G8728	Lipid profile not perf	Fasting lipid profile not performed, reason not given	20161231
G8757	Copd mg qual act perform	All quality actions for the applicable measures in the chronic obstructive pulmonary disease (copd) measures group have been performed for this patient	20161231
G8758	Ibd mg qual act perform	All quality actions for the applicable measures in the inflammatory bowel disease (ibd) measures group have been performed for this patient	20161231
G8759	Osa mg qual act perform	All quality actions for the applicable measures in the sleep apnea measures group have been performed for this patient	20161231
G8761	Dementia mg qual act perform	All quality actions for the applicable measures in the dementia measures group have been performed for this patient	20161231
G8762	Pd mg qual act perform	All quality actions for the applicable measures in the parkinson's disease measures group have been performed for this patient	20161231
G8765	Cataract mg qual act perform	All quality actions for the applicable measures in the cataract measures group have been performed for this patient	20161231
G8784	Pt no elig for bp assess	Patient not eligible (e.g., documentation the patient is not eligible due to active diagnosis of hypertension, patient refuses, urgent or emergent situation)	20161231
G8848	Mild osa	Mild obstructive sleep apnea (apnea hypopnea index (ahi) or respiratory disturbance index (rdi) of less than 15)	20161231
G8853	Pos air press not prescribe	Positive airway pressure therapy not prescribed	20161231

G8868	1st course antitnf	Patients receiving a first course of anti-tnf therapy	20161231
G8898	Copd measures group	I intend to report the chronic obstructive pulmonary disease (copd) measures group	20161231
G8899	Inflammatory bowel dis mg	I intend to report the inflammatory bowel disease (ibd) measures group	20161231
G8900	Obstructive sleep apnea mg	I intend to report the sleep apnea measures group	20161231
G8902	Dementia measures group	I intend to report the dementia measures group	20161231
G8903	Parkinson's disease mg	I intend to report the parkinson's disease measures group	20161231
G8906	Cataract measures group	I intend to report the cataract measures group	20161231
G8927	Adj chem pres ajcc iii	Adjuvant chemotherapy referred, prescribed or previously received for ajcc stage iii, colon cancer	20161231
G8928	Adj chem not pres rsn spec	Adjuvant chemotherapy not prescribed or previously received, for documented reasons (e.g., medical co-morbidities, diagnosis date more than 5 years prior to the current visit date, patient's diagnosis date is within 120 days of the end of the 12 month reporting period, patient's cancer has metastasized, medical contraindication/allergy, poor performance status, other medical reasons, patient refusal, other patient reasons, patient is currently enrolled in a clinical trial that precludes prescription of chemotherapy, other system reasons)	20161231
G8929	Adj cmo not pres rsn not gvn	Adjuvant chemotherapy not prescribed or previously received, reason not given	20161231
G8940	Scr dep pos, no plan done	Screening for depression documented as positive, a follow-up plan not completed, documented reason	20161231
G8948	No neuropsych symptoms	No neuropsychiatric symptoms	20161231
G8953	Oncology mg qual act perform	All quality actions for the applicable measures in the oncology measures group have been performed for this patient	20161231
G8977	Oncology measures grp	I intend to report the oncology measures group	20161231
G9203	Hep c rna done prior to med	Rna testing for hepatitis c documented as performed within 12 months prior to initiation of antiviral treatment for hepatitis c	20161231
G9204	No reason for no hep c rna	Rna testing for hepatitis c was not documented as performed within 12 months prior to initiation of antiviral treatment for hepatitis c, reason not given	20161231
G9205	Hep c antiviral started	Patient starting antiviral treatmentfor hepatitis c during the measurement period	20161231
G9206	Hep c therapy started	Patient starting antiviral treatment for hepatitis c during the measurement period	20161231
G9207	Hep c genotype prior to med	Hepatitis c genotype testing documented as performed within 12 months prior to initiation of antiviral treatment for hepatitis c	20161231
G9208	No reason for no hep c geno	Hepatitis c genotype testing was not documented as performed within 12 months prior to initiation of antiviral treatment for hepatitis c, reason not given	20161231
G9209	Hep c rna 4to12 wk after med	Hepatitis c quantitative rna testing documented as performed between 4-12 weeks after the initiation of antiviral treatment	20161231

G9210	No hepc rna after med docrsn	Hepatitis c quantitative rna testing not performed between 4-12 weeks after the initiation of antiviral treatment for documented reason(s) (e.g., patients whose treatment was discontinued during the testing period prior to testing, other medical reasons, patient declined, other patient reasons)	20161231
G9211	No hepc rna after med no rsn	Hepatitis c quantitative rna testing was not documented as performed between 4-12 weeks after the initiation of antiviral treatment, reason not given	20161231
G9217	No pcp proph low cd4 norsn	Pcp prophylaxis was not prescribed within 3 months of low cd4+ cell count below 200 cells/mm3, reason not given	20161231
G9219	No oder pjp for med reason	Pneumocystis jiroveci pneumonia prophylaxis not prescribed within 3 months of low cd4+ cell count below 200 cells/mm3 for medical reason (i.e., patient's cd4+ cell count above threshold within 3 months after cd4+ cell count below threshold, indicating that the patient's cd4+ levels are within an acceptable range and the patient does not require pcp prophylaxis)	20161231
G9222	Pjp proph ordered low cd4	Pneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low cd4+ cell count below 200 cells/mm3	20161231
G9233	Tkr composite	All quality actions for the applicable measures in the total knee replacement measures group have been performed for this patient	20161231
G9234	Tkr intent	I intend to report the total knee replacement measures group	20161231
G9235	Gs mg composite	All quality actions for the applicable measures in the general surgery measures group have been performed for this patient	20161231
G9236	Op rad mg composite	All quality actions for the applicable measures in the optimizing patient exposure to ionizing radiation measures group have been performed for this patient	20161231
G9237	Gs mg intent	I intend to report the general surgery measures group	20161231
G9238	Op rad mg intent	I intend to report the optimizing patient exposure to ionizing radiation measures group	20161231
G9244	Antiviral not ordered	Antiretroviral therapy not prescribed	20161231
G9245	Antiviral ordered	Antiretroviral therapy prescribed	20161231
G9324	Not all data norsn	All necessary data elements not included, reason not given	20161231
G9435	Asp presc disch	Aspirin prescribed at discharge	20161231
G9436	Asp not presc doc reas	Aspirin not prescribed for documented reasons (e.g., allergy, medical intolerance, history of bleed)	20161231
G9437	Asp not presc disch	Aspirin not prescribed at discharge	20161231
G9438	P2y inhib presc	P2y inhibitor prescribed at discharge	20161231
G9439	P2y inhib not presc doc reas	P2y inhibitor not prescribed for documented reasons (e.g., allergy, medical intolerance, history of bleed)	20161231
G9440	P2y inhib not presc	P2y inhibitor not prescribed at discharge	20161231
G9441	Statin presc disch	Statin prescribed at discharge	20161231
G9442	Statin not presc doc reas	Statin not prescribed for documented reasons (e.g., allergy, medical intolerance)	20161231
G9443	Statin not presc disch	Statin not prescribed at discharge	20161231
G9463	Sinusitis intent	I intend to report the sinusitis measures group	20161231
G9464	Sinusitis comp	All quality actions for the applicable measures in the sinusitis measures group have been performed for this patient	20161231
G9465	Aoe intent	I intend to report the acute otitis externa (aoe) measures group	20161231

G9466	Aoe comp	All quality actions for the applicable measures in the aoe measures group have been performed for this patient	20161231
G9467	Recd cortico >=10mg/day >60d	Patient who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills within the last twelve months	20161231
G9499	No start/rec antivir tx hep c	Patient did not start or is not receiving antiviral treatment for hepatitis c during the measurement period	20161231
G9572	Phq-scr >9 doc in 12m time	Index date phq-score greater than 9 documented during the twelve month denominator identification period	20161231
G9581	Md doc, door to punc tm >2hr	Door to puncture time of greater than 2 hours for reasons documented by clinician (e.g., patients who are transferred from one institution to another with a known diagnosis of cva for endovascular stroke treatment; hospitalized patients with newly diagnosed cva considered for endovascular stroke treatment)	20161231
G9619	Doc rsn no scr uter malig	Documentation of reason(s) for not screening for uterine malignancy (e.g., prior hysterectomy)	20161231
G9650	Doc pt no ther chg or contra	Documentation that the patient declined therapy change or has documented contraindications (e.g., experienced adverse effects or lack of efficacy with all other therapy options) in order to achieve better disease control as measured by pga, bsa, pasi, or dlqi	20161231
G9652	Pt tx sys bio med psori 6mth	Patient has been treated with a systemic or biologic medication for psoriasis for at least six months	20161231
G9653	Pt no tx sys bio rx 6 mths	Patient has not been treated with a systemic or biologic medication for psoriasis for at least six months	20161231
G9657	Toc dur aneth to icu	Transfer of care during an anesthetic or to the intensive care unit	20161231
G9667	Doc med rsn no stat tx/presc	Documentation of medical reason(s) for not currently being a statin therapy user or receive an order (prescription) for statin therapy (e.g., patient with adverse effect, allergy or intolerance to statin medication therapy, patients who have an active diagnosis of pregnancy or who are breastfeeding, patients who are receiving palliative care, patients with active liver disease or hepatic disease or insufficiency, patients with end stage renal disease (esrd), and patients with diabetes who have a fasting or direct ldl-c laboratory test result < 70 mg/dl and are not taking statin therapy)	20161231
G9669	Intend rpt mult chr msr grp	I intend to report the multiple chronic conditions measures group	20161231
G9670	Qty act mcc mg perf	All quality actions for the applicable measures in the multiple chronic conditions measures group have been performed for this patient	20161231
G9671	Intend rpt dia retin msr grp	I intend to report the diabetic retinopathy measures group	20161231
G9672	Qty act diab retin mg perf	All quality actions for the applicable measures in the diabetic retinopathy measures group have been performed for this patient	20161231
G9673	Intend rpt card prev msr grp	I intend to report the cardiovascular prevention measures group	20161231

G9677	Qty act card prev mg perf	All quality actions for the applicable measures in the cardiovascular prevention measures group have been performed for this patient	20161231
J0760	Colchicine injection	Injection, colchicine, per 1 mg	20161231
J1590	Gatifloxacin injection	Injection, gatifloxacin, 10 mg	20161231
K0901	Ko single upright pre ots	Knee orthosis (ko), single upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, prefabricated, off-the-shelf	20161231
K0902	Ko double upright pre ots	Knee orthosis (ko), double upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, prefabricated, off-the-shelf	20161231
Q4119	Matristem wound matrix	Matristem wound matrix, per square centimeter	20161231
Q4120	Matristem burn matrix	Matristem burn matrix, per square centimeter	20161231
Q4129	Unite biomatrix	Unite biomatrix, per square centimeter	20161231
Q9980	Genvisc, inj, 1mg	Hyaluronan or derivative, genvisc 850, for intra-articular injection, 1 mg	20161231
Q9981	Rolapitant, oral, 1mg	Rolapitant, oral, 1 mg	20161231
S8032	Low dose ct lung screening	Low-dose computed tomography for lung cancer screening	20160930